ASH Myeloma Spotlight

Pembrolizumab (Keytruda), pomalidomide (Pomalyst), and dexamethasone had an objective response rate of 65% and a very good partial response or better rate of 29% for patients with relapsed/refractory multiple myeloma, according to phase II findings presented at the 2016 ASH Annual Meeting.

Data from a prospective assessment of minimal residual disease from the phase III CASTOR and POLLUX studies demonstrated at least a 3-fold increase in conversion to negative MRD status with the addition of daratumumab (Darzalex) to standard-of-care regimens in the treatment of patients with relapsed/refractory multiple myeloma.

Shaji Kumar, MD, professor of medicine, Mayo Clinic, discusses the efficacy seen with venetoclax in multiple myeloma during the ASH Annual Meeting 2016.

Consolidation therapy with bortezomib/lenalidomide/dexamethasone (VRD) followed by maintenance with lenalidomide until progression or toxicity showed promising results over maintenance alone for patients with transplant-eligible multiple myeloma (NDMM) up to 65 years old, according to a final analysis of the EMN02 trial.